TL;DR
CBL-514 is not a peptide. It is a patented small-molecule injectable developed by Caliway Biopharmaceuticals (TWSE: 6919) on a 505(b)(1) new drug path. It is designed to reduce localized subcutaneous fat by selectively pushing adipocytes into apoptosis, shrinking fat-cell number in treated areas rather than only shrinking existing cells.
It is investigational and not FDA-approved. The company is running two global pivotal Phase 3 trials (SUPREME-01 and SUPREME-02). Anything sold online as "CBL-514" is not the Caliway study drug.
If you landed here after searching "CBL-514 peptide," this page exists to correct that framing and point to verified sources. PeptIQ.io is education only: no dosing advice, no vendor links, no treatment recommendations.
Is CBL-514 a peptide?
No. Peptides are chains of amino acids. CBL-514 is described repeatedly in Caliway disclosures and peer-reviewed aesthetic medicine papers as a small-molecule injection, not a peptide hormone, not a GLP-1 analog, and not a growth-hormone fragment.
Retail sites that list "CBL-514 peptide" are mislabeled. They are not selling an FDA-reviewed version of Caliway's compound. Do not interpret catalog names as access to clinical trial material.
For the full compound profile (mechanism, trials, FAQs), see CBL-514 on PeptIQ.
What CBL-514 is supposed to do
Caliway's public description: CBL-514 selectively induces adipocyte apoptosis to reduce subcutaneous fat at the injection site, aiming to avoid necrosis or damage to surrounding tissue. That is a different story from:
- Whole-body weight-loss drugs (semaglutide, tirzepatide, retatrutide) that act on appetite and incretin receptors.
- Kybella (deoxycholic acid), the only FDA-approved injectable for localized fat reduction, limited to submental (under-chin) fat.
CBL-514 targets large-area abdominal subcutaneous fat in its Phase 3 program — a contouring indication Kybella is not approved to treat.
How it differs from Kybella (deoxycholic acid)
| CBL-514 | Kybella (deoxycholic acid) | |
|---|---|---|
| Molecule class | Small molecule (investigational) | Small molecule (approved) |
| Mechanism (as described) | Adipocyte apoptosis | Disrupts adipocyte membranes in treated tissue |
| U.S. regulatory status | Not FDA-approved; Phase 3 | FDA-approved for submental fat only |
| Typical study area | Abdominal subcutaneous fat (trials) | Submental fat (label) |
| NDA pathway (Caliway) | Intended 505(b)(1) | Approved NDA |
Caliway's April 2026 investor materials compared Phase 2b two-grade responder rates (21.2% on active drug vs 0% placebo in one analysis set) to historical Kybella pivotal figures (about 13.4%–18.6% in cited comparators). Those figures come from different indications and trial designs; they are not a head-to-head trial.
Human evidence so far (published and presented)
Phase 2a (abdominal fat)
A 2022 Aesthetic Surgery Journal phase IIa paper reported early human work on targeted adipocyte apoptosis with CBL-514 injections.
Phase 2 (abdominal subcutaneous fat)
A 2025 randomized phase II trial (same report at PubMed PMID 40037659) in Aesthetic Surgery Journal found that 69.6% of CBL-514-treated participants met a prespecified ≥150 mL subcutaneous fat volume loss threshold at 8 weeks after the final treatment vs 0% on placebo (P < .001) in the intention-to-treat set. Injection-site reactions were the most common adverse events and were mostly mild to moderate.
Phase 2b (patient + clinician scales)
A 2026 phase 2b publication added clinician- and patient-reported abdominal fat rating scales plus MRI. Caliway's August 2026 investor conference cited completed study CBL-0205: in the full analysis set, 21.2% of treated participants achieved ≥2-grade improvement on combined physician and patient scales vs 0% placebo (p<0.005), and 63.6% achieved ≥1-grade improvement vs 10.8% placebo (p<0.0001).
Visceral fat subgroup (EASD 2026)
News coverage of Caliway's EASD presentation (News-Medical, Oct 2026; Science News, Oct 2026) described an MRI analysis in a subgroup of phase 2 participants with available scans. Reported patterns included VAT decreases in the active group and increases on placebo at follow-up, with between-group differences on the order of ~17–22% depending on timepoint. Subgroup sizes were small; this is exploratory, not a labeled claim.
Dercum's disease (CBL-514D)
Caliway develops a related formulation CBL-514D for Dercum's disease. A 2026 phase 2a paper studied lipomas in Dercum's disease. The company's September 2026 release said study CBL-0202DD met its pain primary endpoint vs placebo and that topline work continued in related conditions (e.g. lipedema research interest). None of this is an approved Dercum's treatment.
Phase 3: SUPREME program
After FDA discussions, Caliway aligned SUPREME-01 (NCT07140939) on a co-primary endpoint: proportion of participants with ≥2-grade improvement on both PR-AFRS and CR-AFRS scales, with MRI abdominal subcutaneous fat volume as a key secondary endpoint. The trial targets ~320 adults (BMI roughly 18.5–30) across the U.S. and Canada, with up to four monthly treatment courses and substantial injection volume per session in the protocol (study-specific).
SUPREME-02 (NCT07526974) is the parallel pivotal study (~320 subjects; U.S., Canada, Australia). Caliway submitted a U.S. IND for SUPREME-02 in April 2026. As of registry metadata in late 2026, SUPREME-01 was recruiting with first participant dosed in September 2026 (company release).
What we do not know yet: final Phase 3 efficacy, durability years out, visceral-fat claims on a label, combination use with GLP-1 drugs in routine care, pricing, or who (if anyone) will be eligible on an approved label.



